Motilal Oswal Recommends 'Buy' On Jubilant Life Sciences
Motilal Oswal expects Jubilant Life Sciences to deliver a robust performance in the LSI (Life Science Ingredients) segment, driven by an improved business scenario for specialty intermediates and nutritional products due to lower supplies from Chinese competitors and better demand for the Life Science Chemical business.